Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Scharn

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|May 15, 2013
Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding modeHarald Engelhardt, Sabine Schultes, Chris de Graaf, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RASTimothy R Hodges, Jason R Abbott, Andrew J Little, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Cell Reports|September 21, 2017
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6Nina Kerres, Steffen Steurer, Stefanie Schlager, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|May 15, 2013
Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding modeHarald Engelhardt, Sabine Schultes, Chris de Graaf, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RASTimothy R Hodges, Jason R Abbott, Andrew J Little, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Cell Reports|September 21, 2017
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6Nina Kerres, Steffen Steurer, Stefanie Schlager, et al.
Pageof 2